Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

71.24 -0.28 (-0.39%)
Streaming Delayed Price Updated: 12:29 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 101,323
Open 70.97
Bid (Size) 71.18 (2)
Ask (Size) 71.52 (4)
Prev. Close 71.52
Today's Range 69.70 - 71.99
52wk Range 55.02 - 98.40
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Stocks that work for billionaires aren't necessarily appropriate for every investor. 
Via The Motley Fool

Performance

YTD
-7.55%
-7.55%
1 Month
-7.14%
-7.14%
3 Month
-21.36%
-21.36%
6 Month
+11.23%
+11.23%
1 Year
+1.61%
+1.61%

More News

Read More
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Analyst Ratings For Axsome Therapeutics
Via Benzinga
2 Under-the-Radar Growth Stocks to Consider
Via The Motley Fool
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Via InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Via Benzinga
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Via The Motley Fool
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Via InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
Via The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.